These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 20510717)

  • 21. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma.
    Hay ID
    J Surg Oncol; 2006 Dec; 94(8):692-700. PubMed ID: 17131429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [How good is the prognosis in differentiated thyroid gland carcinoma].
    Ommer A; Bottel P; Stremmel W
    Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():192-5. PubMed ID: 9101828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of total thyroidectomy in the management of differentiated thyroid cancer.
    Stephenson BM; Wheeler MH; Clark OH
    Curr Opin Gen Surg; 1994; ():53-9. PubMed ID: 7584009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of radioiodine in management of thyroid cancer: experience with 70 cases.
    Afroz S; Ahmed K; Yasmeen S; Ahmed F; Nisa L
    Bangladesh Med Res Counc Bull; 1992 Dec; 18(2):68-71. PubMed ID: 1303083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation.
    Azrif M; Slevin NJ; Sykes AJ; Swindell R; Yap BK
    Radiother Oncol; 2008 Oct; 89(1):105-13. PubMed ID: 18579244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Not Available].
    Lenschow C; Lindner K; Müller AK; Barth P; Senninger N; Colombo-Benkmann M
    Chirurg; 2016 Mar; 87(3):247-50. PubMed ID: 26223667
    [No Abstract]   [Full Text] [Related]  

  • 27. Update on recent developments in the therapy of differentiated thyroid cancer.
    Middendorp M; Grünwald F
    Semin Nucl Med; 2010 Mar; 40(2):145-52. PubMed ID: 20113682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Surgical therapy of differentiated thyroid gland carcinoma].
    Walgenbach S; Sternheim E; Bittinger F; Junginger T
    Zentralbl Chir; 1997; 122(4):252-8. PubMed ID: 9221635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thyroperoxidase: a tumor marker for post-therapeutic follow-up of differentiated thyroid carcinomas? Results of a time course study.
    Franke WG; Zöphel K; Wunderlich GR; Mat R; Kühne A; Schimming C; Kropp J; Bredow J
    Cancer Detect Prev; 2000; 24(6):524-30. PubMed ID: 11198265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of postsurgical stimulated thyroglobulin levels after initial radioactive iodine therapy in well-differentiated thyroid carcinoma.
    Sawka AM; Orlov S; Gelberg J; Stork B; Dowar M; Shaytzag M; Tabatabaie V; Freeman JL; Walfish PG
    Head Neck; 2008 Jun; 30(6):693-700. PubMed ID: 18098308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Follow-up of differentiated thyroid carcinoma.
    Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
    Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contemporary management of papillary carcinoma of the thyroid gland.
    Rosenbaum MA; McHenry CR
    Expert Rev Anticancer Ther; 2009 Mar; 9(3):317-29. PubMed ID: 19275510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hormonal therapy in differentiated carcinoma of the thyroid gland].
    Francia G; Davì MV; Petroziello A; Sussi PL
    Chir Ital; 1994; 46(4):56-8. PubMed ID: 7882445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in the medical management of differentiated thyroid carcinoma and their impact on the surgical approach.
    Van den Bruel A; Vauterin T; Poorten VV; Decallonne B
    Acta Chir Belg; 2007 Jun; 107(3):271-8. PubMed ID: 17685252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thyroid peroxidase (TPO) as a tumor marker in the follow-up of differentiated thyroid carcinomas with surgical and ablative radioiodine therapy. An assessment after evaluation.
    Franke WG; Zöphel K; Wunderlich G; Kühne A; Schimming C; Kropp J; Bredow J
    Anticancer Res; 1999; 19(4A):2711-6. PubMed ID: 10470226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postoperative radioactive iodine administration for differentiated thyroid cancer patients.
    Lepoutre-Lussey C; Deandreis D; Leboulleux S; Schlumberger M
    Curr Opin Endocrinol Diabetes Obes; 2014 Oct; 21(5):363-71. PubMed ID: 25119656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Main trends and controversies in treatment of patients with diffuse toxic goiter and thyroid gland cancer].
    Romanchishen AF; Vabalaĭte KV
    Vestn Khir Im I I Grek; 2011; 170(3):58-63. PubMed ID: 21848241
    [No Abstract]   [Full Text] [Related]  

  • 38. Differentiated thyroid cancer: an update.
    Wang TS; Roman SA; Sosa JA
    Curr Opin Oncol; 2011 Jan; 23(1):7-12. PubMed ID: 20861795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-Term Follow-Up for Differentiated Thyroid Carcinoma Patients: A Reconsideration.
    van der Wardt RA; Persoon AC; Klein Hesselink EN; Links TP
    Thyroid; 2017 Mar; 27(3):475-476. PubMed ID: 28049373
    [No Abstract]   [Full Text] [Related]  

  • 40. Management of papillary thyroid cancer patients in absence of postoperative radioiodine remnant ablation: tailoring follow-up by neck sonography.
    Durante C; Filetti S
    J Clin Endocrinol Metab; 2011 Oct; 96(10):3059-61. PubMed ID: 21795452
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.